Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."
This patent covers compounds including clavulanic acid and moxalactam for the treatment of neurological disorders such as depression, anxiety, dementia, Alzheimer's disease and Parkinson's disease, as well as their use and pharmaceutical formulation.
Rick Soni, President of Rexahn, noted, "Obtaining this European patent coverage for clavulanic acid and moxalactam broadens and strengthens our CNS-related portfolio, which includes Serdaxin®, currently in Phase II clinical trials."
Source: Rexahn Pharmaceuticals, Inc.
Related Post
- Malignant Mesothelioma Following Treatment for Hodgkin's Disease
- Vitamin C helps identify more aggressive or treatment resistant tumours
- U.S. physicians spend more time, money for interaction with health plans than Canadian doctors
- Roadmap to Overcome Obstacles for Using Induced Pluripotent Stem Cells
- Human Brain Cells Created from Skin Cells: Potential for Alzheimer’s
- Canada Blocks UN Asbestos Resolution
- Erionite in North Dakota roads may increase risk of mesothelioma
- Two-Stage Nanoparticle Improves Chemotherapy Delivery
- New potential anti-tumor agents might effectively treat mesothelioma
- Chemotherapy Drug Shortage Puts Patients At Risk
- Vitamin C helps identify more aggressive or treatment resistant tumours
- U.S. physicians spend more time, money for interaction with health plans than Canadian doctors
- Roadmap to Overcome Obstacles for Using Induced Pluripotent Stem Cells
- Human Brain Cells Created from Skin Cells: Potential for Alzheimer’s
- Parkinson's Disease Support
- Parkinson's Disease Treatment
- Parkinson's Disease Research
- Parkinson's Disease Pathophysiology
- Parkinson's Disease Prognosis
- Parkinson's Disease Diagnosis